8-K: GeneDx Exceeds 2025 Revenue, Projects Strong 2026 Growth

GeneDx Holdings Corp. reported robust fourth quarter and full year 2025 financial results, surpassing revenue guidance and reaffirming strong growth projections for 2026 driven by exome and genome testing.

Summary

• Fourth quarter 2025 revenues grew to $121.0 million, an increase of 27% year-over-year (37% excluding a one-time 2024 benefit).
• Full year 2025 revenues grew to $427.5 million, an increase of 41% year-over-year (45% excluding a one-time 2024 benefit), exceeding the previous guidance of $425 to $428 million.
• Exome and genome test revenue increased to $104.0 million in Q4 2025 (up 32% year-over-year, 42% excluding a one-time 2024 benefit) and $360.3 million for full year 2025 (up 54% year-over-year, 58% excluding a one-time 2024 benefit).
• Exome and genome test result volume grew to 27,761 in Q4 2025 (up 34.3% year-over-year) and 97,271 for full year 2025 (up 30.5% year-over-year).
• Adjusted gross margin expanded to 71% for both Q4 2025 and full year 2025, up from 70% in Q4 2024 and 65% for full year 2024.
• Adjusted net income was $4.4 million in Q4 2025 and $41.8 million for full year 2025, compared to $17.5 million and $9.4 million respectively in 2024.
• GAAP net loss was $17.7 million for Q4 2025 and $21.0 million for full year 2025.
• Cash, cash equivalents, marketable securities and restricted cash totaled $172.3 million as of December 31, 2025.
• Management reaffirmed full year 2026 guidance, expecting revenues of $540 to $555 million, 33-35% growth in exome and genome revenue and volume, adjusted gross margin of at least 70%, and positive adjusted net income.
• Key business highlights include the launch of GeneDx Infinity, expansion into general pediatrics and prenatal diagnostics, introduction of ultraRapid genome sequencing, securing Medicaid coverage in 8 new states, FDA Breakthrough Device designation, acquisition of Fabric Genomics, and leadership in genomic newborn screening initiatives.

Sentiment

Score: 8

Explanation: StockSavvy.ai views this as a strong report, demonstrating consistent execution on strategic initiatives and exceeding revenue guidance, with positive momentum for future growth despite a lower adjusted net income in Q4 compared to the prior year due to specific factors.

Positives

• Full year 2025 revenue of $427.5 million exceeded the upper end of the company's guidance range of $425 to $428 million.
• Reported strong year-over-year total revenue growth of 41% for full year 2025 (45% excluding a one-time 2024 benefit).
• Achieved significant growth in exome and genome test revenue, up 54% for full year 2025 (58% excluding a one-time 2024 benefit).
• Accelerated exome and genome volume growth to 34.3% year-over-year in Q4 2025 and 30.5% for full year 2025.
• Adjusted gross margin expanded to 71% for both Q4 and full year 2025, indicating improved operational efficiency.
• Achieved positive adjusted net income of $41.8 million for full year 2025, a substantial increase from $9.4 million in 2024.
• Maintained a robust cash position of $172.3 million as of December 31, 2025.
• Successfully launched GeneDx Infinity, the world's largest and most diverse rare disease dataset, enhancing diagnostic capabilities.
• Expanded strategically into large, underpenetrated markets such as general pediatrics and prenatal diagnostics with new offerings like GenomeDx Prenatal.
• Introduced ultraRapid genome sequencing, providing accelerated genomic insights in as soon as 48 hours for critically ill patients.
• Secured Medicaid coverage for exome and genome sequencing in 8 new states, expanding patient access.
• Granted FDA Breakthrough Device designation for GeneDx ExomeDx and GenomeDx, underscoring leadership in genomic medicine.
• Acquired Fabric Genomics, expanding global delivery of genomic insights.
• Advanced leadership in genomic newborn screening through participation in key initiatives like BEACONS, Sunshine Genetics Network, and the GUARDIAN study.
• Partnered with Komodo Health to enhance GeneDx Infinity with real-world patient insights.
• Unveiled Multiscore, an advanced AI-powered decision support tool to improve diagnostic efficiency.
• Surpassed 1,100 total peer-reviewed studies, demonstrating strong clinical and research leadership.
• Reaffirmed strong full year 2026 guidance for revenue, exome and genome growth, and positive adjusted net income, signaling continued confidence in future performance.

Negatives

• Adjusted net income for Q4 2025 was $4.4 million, a significant decrease compared to $17.5 million in Q4 2024.
• Reported GAAP net losses of $17.7 million for Q4 2025 and $21.0 million for full year 2025.
• Adjusted total operating expenses increased to $81.8 million in Q4 2025, representing 68% of revenue, up from 52% of revenue in Q4 2024, indicating higher operational costs relative to revenue in the quarter.
• Comparative 2024 revenues, gross margin, and net income included a $6.8 million discrete benefit from a multi-year appeal recovery, which impacts year-over-year comparisons when not adjusted.

Risks

• The ability to implement business plans, goals, and forecasts, and identify and realize additional opportunities.
• The risk of downturns and a changing regulatory landscape in the highly competitive healthcare industry.
• The size and growth of the market in which GeneDx operates.
• The ability to pursue its new strategic direction.
• Other risks and uncertainties described in the Risk Factors section of the Annual Report on Form 10-K for the fiscal year ended December 31, 2024, and other documents filed with the SEC.

Future Outlook

Management expects full year 2026 revenue to be between $540 million and $555 million, with exome and genome revenue and volume growth projected at 33% to 35%. Adjusted gross margin is anticipated to be at least 70%, and adjusted net income is expected to be positive.

Management Comments

• "The unmet need for early, accurate genomic diagnosis is enormous, and families are waiting far too long for answers. GeneDx is uniquely positioned to deliver for patients, clinicians, and partners – and our results demonstrate that." Katherine Stueland, President and CEO.
• "Our team is executing at the highest level, our platform continues to scale, and GeneDx InfinityTM gives us a compounding data advantage that strengthens with every test we run." Katherine Stueland, President and CEO.
• "The business has never been in a better position for continued growth and success. As we enter 2026, we will layer new growth drivers onto an already powerful foundation – expanding into large, underpenetrated markets where patients are waiting for a diagnosis that GeneDx can provide today." Katherine Stueland, President and CEO.

Industry Context

StockSavvy.ai notes that GeneDx's strong performance and strategic expansions, particularly into general pediatrics and prenatal diagnostics, align with the broader industry trend of increasing adoption of genomic testing as a first-tier diagnostic tool. The FDA Breakthrough Device designation and growing Medicaid coverage underscore the increasing recognition of genomics' critical role in early and accurate disease diagnosis, positioning GeneDx as a leader in a rapidly evolving precision medicine landscape. The acquisition of Fabric Genomics and participation in genomic newborn screening initiatives further solidify its competitive advantage in data-driven genomic insights.

Comparison to Industry Standards

• GeneDx Infinity, with over 1 million exomes and genomes and 8 million phenotypic data points, represents the world's largest and most diverse rare disease dataset, providing a significant competitive advantage over smaller genomic testing providers.
• The company's diagnostic yield and speed, with ultraRapid genome sequencing delivering results in as soon as 48 hours for NICU/PICU patients, sets a high benchmark compared to traditional diagnostic odysseys that can take years.
• The American Academy of Pediatrics' updated guidance in June 2025, recommending exome and genome sequencing as first-tier tests for children with global developmental delay or intellectual disability, validates GeneDx's strategic focus and positions its offerings as a new standard of care, potentially outperforming older, less comprehensive genetic tests.
• GeneDx's 80% market share among geneticists and contracts with 80% of covered lives, including all large national commercial payers, indicates a strong market penetration and acceptance compared to emerging or niche genomic testing companies.
• The company's participation in multi-state genomic newborn screening initiatives like BEACONS and Florida's Sunshine Genetics Network, and the GUARDIAN study (sequencing >22,000 newborns), demonstrates leadership in a nascent but critical area of genomics, potentially setting standards for future widespread adoption.

Legal Proceedings

• The reconciliation of adjusted net income for Q4 2025 and full year 2025 includes legal costs and a reserve for a certain litigation matter.
• The reconciliation of adjusted net income for full year 2024 included reserves net of insurance for a certain litigation matter.

Stakeholder Impact

• Shareholders are likely to view the strong revenue growth, exceeding guidance, expanding gross margins, and positive adjusted net income as favorable, indicating improving financial health and future growth potential. The at-the-market offering represents capital generation but also potential dilution.
• Patients will benefit significantly from expanded access to advanced genomic testing, including ultraRapid genome sequencing and GenomeDx Prenatal, leading to faster and more accurate diagnoses.
• Clinicians gain enhanced diagnostic tools like GeneDx Infinity and Multiscore, supported by updated guidelines from the American Academy of Pediatrics, facilitating better patient care.
• Payers may see long-term benefits through early, precise diagnoses that can lead to more effective and targeted treatments, potentially reducing overall healthcare costs.
• Employees are likely to experience a stable and growing work environment given the company's strategic expansions and strong performance.

Next Steps

• Host a conference call on February 23, 2026, at 8:30 a.m. ET to discuss financial results.
• Expand into general pediatrics in the second half of 2026.
• Launch GenomeDx Prenatal in the second half of 2026.
• Expand into adult specialists, focusing on neurologists, in the second half of 2026.
• Continue to expand international footprint with sales representatives in key geographies.
• Participate in the BEACONS initiative to enroll up to 30,000 newborns in genomic newborn screening over the next three years.
• Dedicated team of approximately 50 sales representatives expected to drive impact in general pediatrics at the end of 2026 and into 2027.

Key Dates

Recommendation

GeneDx delivered a strong financial performance, exceeding full-year 2025 revenue guidance and demonstrating robust growth in its core exome and genome testing segments. The expansion of adjusted gross margins and positive adjusted net income, coupled with a healthy cash position, indicates improving operational efficiency and financial health. Strategic initiatives like the launch of GeneDx Infinity, expansion into new markets (pediatrics, prenatal), FDA Breakthrough Device designation, and leadership in genomic newborn screening position the company for sustained high growth. The reaffirmed strong 2026 guidance further reinforces confidence in its future trajectory within the rapidly expanding precision medicine market. Despite a lower adjusted net income in Q4 2025 compared to Q4 2024, the overall trend and strategic advancements warrant a strong buy recommendation for long-term investors.

Keywords

Genomics, Rare Disease Diagnosis, Exome Sequencing, Genome Sequencing, Precision Medicine, Genetic Testing, Biopharma, AI in Genomics, Healthcare Technology, FDA Breakthrough Device, Newborn Screening, Prenatal Diagnostics, Medicaid Coverage, Financial Results, Earnings Report, GeneDx Holdings Corp.